HR Execs on the Move

Intercept Pharmaceuticals

www.interceptpharma.com

 
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Douglas Maneval
Executive Director R&D Quality Profile
Antonio Civitarese
Sr Director, Director of Clinical Research and Development Profile
Michelle Berrey
President R&D and Chief Medical Officer Profile
Dick Lancaster
Vice President, Product Development Profile
Andrew Saik
Chief Financial Officer Profile

Jobs

Director, Human Resources

Intercept Pharmaceuticals San Diego, CA
Accountable for developing and implementing U.S. Regional (San Diego office) HR strategy, in alignment with global HR direction & strategy, to ensure delivery of HR support that enables the U.S. organization to meet or exceed short- and long-term business objectives. While partnering closely with U.S. business operations leaders, areas of ...

Similar Companies

Proacta

Proacta Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Connections Behavior Planning & Intervention

ABA Therapy for children with ASD, EBD, & developmental disabilities. We serve King County, WA including Kent, Renton, Seattle, Kirkland, Redmond, & more.

NCS PHARMACEUTICALS

NCS PHARMACEUTICALS is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.